Short answer
Altimmune, Inc. (ALT) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$32M
- −66.2% YoY · −38.5% QoQ
- EPS (diluted)
- −$0.16
- +23.8% YoY · −45.5% QoQ
Source: XBRL data from the Altimmune, Inc. (ALT) Q3 2026 10-Q on SEC EDGAR. USD.
Altimmune, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0, down 100% YoY from $5,000
- Net loss $31.6M vs $19.0M YoY, operating loss $35.7M vs $20.9M
- Best-performing line: MASH R&D $10.7M, up $6.9M YoY; AUD R&D $1.9M, down $1.4M
- Cash used in operations $82.9M, investments $451.0M at September 30, 2026
- April offering raised $211.1M net; management expects funding for at least twelve months, with tariff and inflation risks ahead
Risk Factors
- No material changes from the March 6, 2026 Form 10-K risk factors
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Altimmune, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.